We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kiora Pharmaceuticals Inc (KPRX) USD0.01

Sell:$0.36 Buy:$0.47 Change: $0.0529 (12.66%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.0529 (12.66%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
Change: $0.0529 (12.66%)
Market closed |  Prices as at close on 30 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Its wholly owned subsidiaries include Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH, Bayon Therapeutics, Inc. and Kiora Pharmaceuticals Pty Ltd.

Contact details

1371 EAST 2100 SOUTH, SUITE 200
United States
+1 (781) 7888869

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.14 million
Shares in issue:
12.66 million
United States
US dollar

Key personnel

  • Paul Chaney
    Executive Chairman of the Board
  • Brian Strem
    President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Director
  • Franz Obermayr
    Executive Vice President - Clinical Development
  • Eric Daniels
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.